Lilly's Pain Is Amgen, Regeneron And Esperion's Gain
October 12, 2015 at 10:20 AM EDT
Shares of Esperion Therapeutics Inc. surged 4.4%, Regeneron Pharmaceuticals Inc. climbed 3.2% and Amgen Inc. ran up 1.9% in morning trade Monday, after RBC Capital analyst Michael Yee said the companies could benefit from Eli Lilly & Co.'s discontinuation of development of its heart disease treatment, evacetrapib.
